5CV.DE Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 11:35):

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA)...

Stats
Today's Volume	135 574
Average Volume	76 982.00
Market Cap	472.39M
EPS	€-0.217 ( 2023-09-30 )
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-1.440
ATR14	€0.0110 (0.52%)

Volume Correlation

Long: -0.09 (neutral)

Short: -0.35 (neutral)

Signal:(34.396) Neutral

CureVac N.V. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

CureVac N.V. Correlation - Currency/Commodity

0.42
( neutral )

0.81
( strong )

0.00
( neutral )

-0.53
( weak negative )

0.00
( neutral )

0.47
( neutral )

CureVac N.V. Financials

Annual	2022
Revenue:	€67.42M
Gross Profit:	€-116.57M (-172.91 %)
EPS:	€-1.320

Q3	2023
Revenue:	€16.48M
Gross Profit:	€-7.80M (-47.31 %)
EPS:	€-0.220

Q2	2023
Revenue:	€7.58M
Gross Profit:	€-18.28M (-241.13 %)
EPS:	€-0.300

Q1	2023
Revenue:	€7.13M
Gross Profit:	€-13.51M (-189.45 %)
EPS:	€-0.270

Financial Reports:

No articles found.

CureVac N.V.

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.